Back to News
Market Impact: 0.2
Rapport Therapeutics Prices $380 Million Stock And Convertible Notes Offerings; Stock Down
Source: Nasdaq
Healthcare & BiotechCredit & Bond MarketsCompany Fundamentals
Rapport Therapeutics priced separate public offerings of common stock and convertible senior notes, alongside a concurrent private placement. The transactions are expected to raise approximately $380 million in gross proceeds before fees; the available article text does not provide further terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
RAPP0.35
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- SK Hynix says the memory-chip shortage will last until 2030—and more than half its production is booked for the next two years
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong
- Microsoft’s strong quarter backs up its stock rebound. Here's our new price target